Nicotinic acid receptor agonists differentially activate downstream effectors - Wikidata - awgldk - TriplyDB

Nicotinic acid receptor agonists differentially activate downstream effectors

Nicotinic acid receptor agonists differentially activate downstream effectors

http://www.wikidata.org/entity/Q28298974

about

beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice The physiological relevance of functional selectivity in dopamine signalling GPR109A and vascular inflammation Niacin stimulates adiponectin secretion through the GPR109A receptor The hypophagic response to heat stress is not mediated by GPR109A or peripheral β-OH butyrate Nicotinic acid activates the capsaicin receptor TRPV1: Potential mechanism for cutaneous flushing.Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.Nicotinic acid receptor abnormalities in human skin cancer: implications for a role in epidermal differentiation.Internalization of the human nicotinic acid receptor GPR109A is regulated by G(i), GRK2, and arrestin3.Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells.Novel HDL-directed pharmacotherapeutic strategies.Biological roles and therapeutic potential of hydroxy-carboxylic Acid receptors.Identification and characterization of distinct C-terminal domains of the human hydroxycarboxylic acid receptor-2 that are essential for receptor export, constitutive activity, desensitization, and internalization.Nicotinic acid: an old drug with a promising future Effects of pyrazole partial agonists on HCA(2) -mediated flushing and VLDL-triglyceride levels in mice.Therapeutic potential of β-arrestin- and G protein-biased agonists.Nicotinic acid is a common regulator of heat-sensing TRPV1-4 ion channels Functionally biased signalling properties of 7TM receptors - opportunities for drug development for the ghrelin receptor.Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.An update of novel screening methods for GPCR in drug discovery.Biased agonism at G protein-coupled receptors: the promise and the challenges--a medicinal chemistry perspective.Gating function of isoleucine-116 in TM-3 (position III:16/3.40) for the activity state of the CC-chemokine receptor 5 (CCR5).Distinct kinetic and spatial patterns of protein kinase C (PKC)- and epidermal growth factor receptor (EGFR)-dependent activation of extracellular signal-regulated kinases 1 and 2 by human nicotinic acid receptor GPR109A.Estimation of the receptor-state affinity constants of ligands in functional studies using wild type and constitutively active mutant receptors: Implications for estimation of agonist bias.Biased and constitutive signaling in the CC-chemokine receptor CCR5 by manipulating the interface between transmembrane helices 6 and 7.Measuring niacin-associated skin toxicity (NASTy) stigmata along with symptoms to aid development of niacin mimetics.Phenolic acids suppress adipocyte lipolysis via activation of the nicotinic acid receptor GPR109A (HM74a/PUMA-G).Unique interaction pattern for a functionally biased ghrelin receptor agonist.Group IIE secretory phospholipase A2 regulates lipolysis in adipocytes.Elucidation of signaling and functional activities of an orphan GPCR, GPR81.Discovery of 4-(phenyl)thio-1H-pyrazole derivatives as agonists of GPR109A, a high affinity niacin receptor.

P2860

Q24654027-D8C10441-0866-47C9-89CB-087483111258 Q27027511-318FC7A0-27D7-45FF-8572-BC3C7A94F977 Q28287747-386BB80F-1C3F-46A7-A238-A7AB97BE809A Q28575089-184D7788-85B5-489A-9821-025C89DF181F Q31051889-A97183E4-6226-4668-8BBF-FE9A55B708A8 Q33778078-90C678D0-12B3-4969-8342-81803D406938 Q33890786-1511ED98-8791-4981-9791-D9C96A91F273 Q33927010-F04FD83B-5AD3-42E1-AAB8-5892C7C5F8D5 Q33991193-448B47DD-328F-4798-8684-4023FA664F91 Q34624990-2471C13D-A0C3-44FE-BA92-B9E90D9538E2 Q35860020-3CB50210-026A-4DAE-894B-18BE4BCE9669 Q35971823-349A9345-18AE-46EE-9759-C67BC723FD67 Q36412846-888016C9-7C3B-4DDA-9E09-95B5B1AA5EC6 Q36497035-13128885-06CA-4FA8-9A62-66C67C3CDA0C Q36619771-D6C60EA8-ACF1-454D-8AC7-4CAFFD6DDBB5 Q36773331-2E297F8D-C884-4DAB-A567-92A9AF458AC8 Q36972642-D8AC5531-86E3-47EB-B926-6EE53E1BADC8 Q37337832-F7F1C586-82D7-4782-A2E2-D29AE0D0EE8C Q37376937-106EE9DF-3EF0-429B-847C-86268B440250 Q38020237-10767C0E-F8F3-485F-8B7A-95BEA02856DC Q38209355-3C5BEB40-3988-4CD1-92A6-BE07452B5C2B Q38274861-626341C7-2164-4D7D-9FC8-C6375BA3CFA5 Q38418432-9646FAE7-2E2D-42A4-B96D-4475796CBB16 Q39304510-3AF36D40-37C3-4517-A68C-8C82C217AFE7 Q40323977-B3F62E86-F2FB-49B0-9110-31CB299E116E Q40365888-0477F01C-B6BE-4120-BF8E-D2DC96432EDD Q41846905-741C1C7B-DAB4-45DF-BCD2-742D79A59CEB Q42064855-DE1708D6-034E-45B6-BABF-7F4F1C0CACFD Q42829572-5683F83B-1116-4DFB-84C2-D2E03EDB6811 Q46823789-B772DDFB-4A8B-42CD-851A-02DE49FBDD9E Q51744937-4BE73020-22CD-442A-ADDA-89210DD7D07B

P2860

Nicotinic acid receptor agonists differentially activate downstream effectors

http://www.wikidata.org/entity/Q28298974

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Nicotinic acid receptor agonists differentially activate downstream effectors

@ast

Nicotinic acid receptor agonists differentially activate downstream effectors

@en

Nicotinic acid receptor agonists differentially activate downstream effectors

@nl

type

label

Nicotinic acid receptor agonists differentially activate downstream effectors

@ast

Nicotinic acid receptor agonists differentially activate downstream effectors

@en

Nicotinic acid receptor agonists differentially activate downstream effectors

@nl

prefLabel

Nicotinic acid receptor agonists differentially activate downstream effectors

@ast

Nicotinic acid receptor agonists differentially activate downstream effectors

@en

Nicotinic acid receptor agonists differentially activate downstream effectors

@nl

P1433

Q28298974-45E6081E-7468-4FE2-9431-5C261740306C

P1476

Q28298974-866467F2-6BDD-4FB7-B2BE-BAEB3BE6DAEA

P2093

Q28298974-048AA9C9-9858-45DC-B04D-CF6CA5ADB3CE

Q28298974-178F2881-8D42-4723-9BC4-FD278D45543C

Q28298974-23E05886-68B6-47F4-829F-EE58C4CAEAF9

Q28298974-2AF30D72-BED1-4A2C-93FE-02BA4EC03A87

Q28298974-2C1A1770-634C-40A3-8409-BEB6BFDC4921

Q28298974-451FDBF0-93F7-47AC-9E8D-A81B2D50A242

Q28298974-4608C801-A842-4FC0-99A6-8A3F3BBB7C38

Q28298974-65336342-E0A0-43E4-85C9-AB1181119FED

Q28298974-6BA1C563-A9A6-4270-B893-D466D3625C57

Q28298974-7491762A-B7DE-4C91-9B7F-2C557E6A68B4

P2860

Q28298974-06569194-DD72-4296-85CD-C257516AA492

Q28298974-11B74B93-B5A8-41F9-A589-E179ECBC8609

Q28298974-15FA534B-72FA-4E45-8A37-DFCA6B5A132B

Q28298974-1C0AE76D-E044-4F5A-84E9-6499F3C3306C

Q28298974-2E2FC3CB-79A3-489F-9C40-596B660CE743

Q28298974-2FDBF11E-42CC-4B4B-B656-817A36B101BE

Q28298974-3915A14F-C173-4BE2-B2A5-8F242BFDA935

Q28298974-3EEE2EE3-95E0-4DD9-A9E6-797C5714EBE0

Q28298974-40A361B5-4AD9-490F-9D3C-B2C1D64C9572

Q28298974-45A08353-CBE2-4340-8250-A942356B38D8

P304

Q28298974-920B72D6-7222-4053-9E17-1F0DB7A8FFFF

P31

Q28298974-307FC8DD-5AFF-45FB-A212-690410FF583D

P356

Q28298974-2A0C56D3-EE0B-4B89-8678-98A9D407D744

P407

Q28298974-FEA705DA-B241-4B9E-9C57-F370EB5256D8

P433

Q28298974-D272DB03-F599-42D6-8CA9-8E2BA2BD12E4

P478

Q28298974-F4B79664-3A6E-47E4-A26E-3DAFEA17E0C8

P577

Q28298974-5877EBA2-33EE-4D68-B7A0-5E9F12086F10

P698

Q28298974-F3599A53-9E12-4BCE-AE75-FF83BFB1A37F

P356

P1433

Journal of Biological Chemistry

P1476

Nicotinic acid receptor agonists differentially activate downstream effectors

@en

P2093

Daniel T Connolly

http://www.w3.org/2001/XMLSchema#string

Dominic P Behan

http://www.w3.org/2001/XMLSchema#string

Dominique Maciejewski-Lenoir

http://www.w3.org/2001/XMLSchema#string

Doug Boatman

http://www.w3.org/2001/XMLSchema#string

Graeme Semple

http://www.w3.org/2001/XMLSchema#string

Hong Zheng

http://www.w3.org/2001/XMLSchema#string

Ibragim Gaidarov

http://www.w3.org/2001/XMLSchema#string

Jeremy G Richman

http://www.w3.org/2001/XMLSchema#string

Jill S Cameron

http://www.w3.org/2001/XMLSchema#string

Linda Cham

http://www.w3.org/2001/XMLSchema#string

P2860

Heterozygous alpha 2A-adrenergic receptor mice unveil unique therapeutic benefits of partial agonists.

GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing

Molecular identification of nicotinic acid receptor

Molecular identification of high and low affinity receptors for nicotinic acid

PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect

Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.

Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells.

Langerhans cells release prostaglandin D2 in response to nicotinic acid.

Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans.

A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients.

P304

18028-36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M701866200

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

282

http://www.w3.org/2001/XMLSchema#string

P577

2007-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17452318

http://www.w3.org/2001/XMLSchema#string